Morphosys to enrol more patients in tafasitamab’s B-MIND trial

MorphoSys expects to report top-line data from the B-MIND trial in 2022. Credit: MorphoSys AG.

MorphoSys has said that an independent data monitoring committee (IDMC) recommended increasing the size of tafasitamab’s Phase III B-MIND clinical trial.

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges

By Suvoda

By clicking the Download Free Case Study button, you accept the terms and conditions and acknowledge that your data will be used as described in the Suvoda privacy policy

By downloading this Case Study, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tafasitamab is designed as a humanised Fc-engineered monoclonal antibody to target CD19, which is expressed on various B-cell malignancies.

B-MIND is a Phase II/III trial assessing tafasitamab in combination with bendamustine, a chemotherapeutic agent, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).

The investigational drug combination was compared to rituximab, an anti-CD20 antibody, and bendamustine combination.

Patients not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) were recruited to participate in B-MIND.

At interim analysis for futility, the IDMC reviewed efficacy data from the overall patient population and the biomarker-positive subpopulation. A low peripheral blood natural killer cell count at baseline was considered as a biomarker.

Based on the results, the committee recommended the company to boost the number of participants from 330 to 450 to increase the study’s statistical power.

MorphoSys said that the analysis data was not shared with the company. Top-line data from the trial are expected to be reported in the first quarter of 2022.

MorphoSys chief development officer Dr Malte Peters said: “DLBCL is a difficult to treat disease and has a high unmet medical need, so new treatment options are highly needed.

“Independent of B-MIND, we are on track to complete our BLA submission to the US FDA for tafasitamab in combination with lenalidomide by the end of 2019 based on the previously reported encouraging results from the L-MIND and Re-MIND clinical studies.”

Tafasitamab in combination with lenalidomide is also undergoing an open-label Phase II trial in relapsed/refractory DLBCL patients. It is being further studied in combination with idelalisib or venetoclax to treat relapsed/refractory CLL/SLL.